Ultragenyx Pharmaceutical (NASDAQ:RARE) released its earnings results on Tuesday. The biopharmaceutical company reported ($1.73) EPS for the quarter, beating analysts’ consensus estimates of ($1.74) by $0.01, Bloomberg Earnings reports. The company had revenue of $16.26 million during the quarter, compared to the consensus estimate of $13.30 million. Ultragenyx Pharmaceutical had a negative return on equity of 40.10% and a negative net margin of 508.70%.
RARE stock traded up $6.11 during trading on Wednesday, hitting $62.92. The stock had a trading volume of 6,704 shares, compared to its average volume of 416,294. Ultragenyx Pharmaceutical has a 1-year low of $37.44 and a 1-year high of $90.98. The company has a market capitalization of $2.87 billion, a price-to-earnings ratio of -8.40 and a beta of 2.26.
In related news, Director William Aliski sold 6,000 shares of the business’s stock in a transaction dated Friday, December 7th. The shares were sold at an average price of $49.69, for a total value of $298,140.00. Following the completion of the transaction, the director now owns 72,610 shares of the company’s stock, valued at approximately $3,607,990.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 8.40% of the company’s stock.
Several research firms have recently issued reports on RARE. Credit Suisse Group set a $59.00 price target on Ultragenyx Pharmaceutical and gave the stock a “hold” rating in a research note on Thursday, November 15th. ValuEngine downgraded Ultragenyx Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Monday, October 29th. JPMorgan Chase & Co. set a $68.00 price target on Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a research note on Saturday, October 27th. Zacks Investment Research raised Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating and set a $50.00 price target for the company in a research note on Tuesday, December 18th. Finally, SunTrust Banks lifted their price target on Ultragenyx Pharmaceutical to $71.00 and gave the stock a “buy” rating in a research note on Wednesday, January 23rd. Eight research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $74.83.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Ticker Report and is owned by of Ticker Report. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/4165565/ultragenyx-pharmaceutical-rare-issues-earnings-results.html.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.
Further Reading: How does a reverse stock split work?
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.